Skip to main content
INNOCARE PHARMA LIMITED logo

INNOCARE PHARMA LIMITED — Investor Relations & Filings

Ticker · 688428 ISIN · CNE100005P56 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688428

About INNOCARE PHARMA LIMITED

https://www.innocarepharma.com/

InnoCare Pharma Limited is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of molecularly targeted therapies for cancer and autoimmune diseases. The company prioritizes the creation of first-in-class and best-in-class drugs to address significant unmet medical needs. Its flagship product, orelabrutinib, is a highly selective Bruton's tyrosine kinase (BTK) inhibitor utilized in the treatment of B-cell malignancies and investigated for autoimmune indications. InnoCare's pipeline includes a diverse range of candidates targeting solid tumors and hematological conditions, leveraging expertise in structural biology and precision medicine. The organization maintains integrated capabilities across research, clinical development, and manufacturing to support its global therapeutic programs.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于诺诚健华医药有限公司使用部分暂时闲置募集资金进行现金管理及以通知存款、协定存款等方式存放募集资金的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor (“保荐机构”) review opinion (“核查意见”) on the use of temporarily idle IPO proceeds for cash management by a listed company. It is a regulatory compliance disclosure under exchange rules (募集资金监管规则) rather than a financial report, earnings release, or other specified category. It does not announce a new report, nor contain financial statements of a quarter or year. Thus it falls under the general “Regulatory Filings” category (RNS).
2026-05-25 Chinese
诺诚健华医药有限公司董事会决议公告
Board/Management Information Classification · 90% confidence The document is titled “董事会决议公告” and details the resolutions passed by the company’s board of directors at a board meeting (e.g., approval of stock incentive vesting, cancellation of unvested shares, use of idle funds). It is not an earnings release, capital market transaction, nor an AGM materials or full financial report. It clearly falls under announcements of board/management decisions.
2026-05-25 Chinese
诺诚健华医药有限公司董事会薪酬委员会关于2024年科创板限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
Share Issue/Capital Change Classification · 82% confidence The document is an official announcement by the Board’s Remuneration Committee confirming the first vesting of restricted shares under the 2024 STAR Market Incentive Plan and the list of eligible grantees. This constitutes an announcement of an employee share issuance (capital change) rather than a management change, earnings release, or full report. Therefore, it fits ‘Share Issue/Capital Change’ (SHA).
2026-05-25 Chinese
诺诚健华医药有限公司关于2024年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告
Share Issue/Capital Change Classification · 90% confidence The document is a formal corporate announcement by InnoCare Pharma Limited (科创板代码 688428) detailing the vesting and issuance of restricted stock under its 2024 restricted stock incentive plan. It provides information on grant numbers, vesting conditions, board approvals, legal opinions, and share issuance specifics. This fits the category of new share issuance/capital change rather than a financial report, management discussion, or regulatory notice. Therefore, it belongs to the "Share Issue/Capital Change" classification (Code: SHA).
2026-05-25 Chinese
上海市方达律师事务所关于诺诚健华医药有限公司2024年科创板限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter issued by a law firm regarding the compliance and approval of a share incentive plan’s vesting and forfeiture under Chinese securities regulations. It is not the underlying share issuance announcement itself nor a financial report, nor is it a managerial or earnings document. Instead, it is a compliance/legal submission serving as a regulatory attachment or filing. Hence, it falls under the catch‐all “Regulatory Filings” category (RNS).
2026-05-25 Chinese
诺诚健华医药有限公司自愿披露关于ICP-054（ZB021）完成首例受试者入组的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement disclosing clinical trial progress (first subject enrollment for drug candidate ICP-054) by the board. It contains no financial statements, no voting results, no management change, and no other specific filing type applies. It is thus a general regulatory announcement best classified as Regulatory Filings (RNS).
2026-05-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.